Jefferies Group reaffirmed their hold rating on shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) in a research report released on Friday morning. They currently have a $16.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $14.00.

Several other research firms have also issued reports on SCMP. Maxim Group reduced their target price on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a buy rating on the stock in a report on Monday, August 1st. Vetr lowered Sucampo Pharmaceuticals from a strong-buy rating to a buy rating and set a $14.00 target price on the stock. in a report on Monday, September 19th. Zacks Investment Research raised Sucampo Pharmaceuticals from a sell rating to a hold rating in a report on Monday, August 8th. Mizuho lowered Sucampo Pharmaceuticals from a buy rating to a neutral rating and set a $13.00 target price on the stock. in a report on Thursday, August 4th. Finally, Northland Securities began coverage on Sucampo Pharmaceuticals in a report on Wednesday, September 7th. They set an outperform rating and a $15.00 target price on the stock. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $17.33.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 15.85 on Friday. Sucampo Pharmaceuticals has a one year low of $9.59 and a one year high of $18.75. The firm’s 50-day moving average price is $12.79 and its 200 day moving average price is $11.84. The company has a market capitalization of $678.67 million, a PE ratio of 53.55 and a beta of 1.62.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. Sucampo Pharmaceuticals had a return on equity of 44.19% and a net margin of 6.29%. The firm had revenue of $57.90 million for the quarter, compared to analyst estimates of $51.30 million. During the same period in the prior year, the firm posted $0.16 EPS. The company’s revenue for the quarter was up 73.4% on a year-over-year basis. Analysts anticipate that Sucampo Pharmaceuticals will post $1.22 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. Zacks Investment Management bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth about $110,000. Boothbay Fund Management LLC bought a new position in shares of Sucampo Pharmaceuticals during the first quarter worth about $114,000. Smith Asset Management Group LP increased its position in shares of Sucampo Pharmaceuticals by 69.5% in the second quarter. Smith Asset Management Group LP now owns 10,730 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 4,400 shares during the period. Princeton Alpha Management LP bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth about $138,000. Finally, Nine Chapters Capital Management LLC bought a new position in shares of Sucampo Pharmaceuticals during the third quarter worth about $142,000. Institutional investors own 41.14% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.